#USA #San Diego #Discovery Life #OncoPro Medium #Tumoroids

Discovery Life Sciences to Launch Tumoroid Cell Lines at Precision Med Tri-Con 2025

HUNTSVILLE, Ala., Feb. 25, 2025 /PRNewswire/ -- Discovery Life Sciences, a leading global provider of biospecimen solutions and lab services, has announced an exciting upcoming product launch. At the Precision Med Tri-Con 2025 event in San Diego, California, from March 11-13, Discovery will unveil its latest innovation — Tumoroid Cell Lines derived from the OncoPro™ Medium.

The Significance of Tumoroid Cell Lines

The Tumoroid Cell Lines represent a major advancement in the field of oncology research. These cell lines are patient-derived and cultivated as three-dimensional (3D) multicellular structures that closely mimic the environment of actual tumors. By using these tumoroids, researchers can bypass several significant hurdles currently faced in cancer study, enabling them to quickly identify potentially life-saving treatments.

"Our tumoroid cell lines are a transformative tool that can help eliminate major barriers to oncology research, providing scientists with a predictive resource to speed up the development of effective therapies," said McLean Collins, President of Biospecimens Products & Services at Discovery.

This innovative addition to Discovery's offerings aligns with the company's ongoing commitment to fostering advancements in cancer research, further complementing its existing suite of cell biology services, including CFC and ADC assays, along with the diverse range of their 10X single-cell portfolio.

Highlights from Tri-Con 2025

During the Precision Med Tri-Con 2025, Discovery's presence will not be limited to just the launch of the Tumoroid Cell Lines. The team, led by Dr. Shawn Fahl, Vice President of Lab Operations and R&D, will engage in several key scientific discussions:

• - Luncheon Presentation: On March 11, Dr. Fahl will discuss how spatial and transcriptomic analyses can accelerate development in his talk titled "From Biorepository to Breakthroughs."
• - Keynote Panel Discussion: The following day, Dr. Fahl will participate in a panel discussing tech trends in precision medicine, highlighting emerging innovations that are shaping the future of healthcare.
• - Poster Presentation: Discovery will also present findings on liquid biopsy workflows in a poster titled "Cell-Free DNA and Beyond A Comprehensive Evaluation of Liquid Biopsy Workflows Across a Global Clinical Biorepository."

Dr. Fahl expressed enthusiasm about sharing knowledge at the event, saying, "We will showcase exciting studies this year, underscoring our dedication to enhancing precision medicine through the integration of advanced technologies and high-quality biospecimens. This is a vital opportunity for engaging with the scientific community and exploring new pathways to advance oncology research together."

A Commitment to Innovation

Discovery Life Sciences continues to make strategic investments in advanced technologies, including AI-enhanced pathology and clinical biomarker testing workflows. These innovations provide researchers with actionable insights drawn directly from high-quality biospecimens.

As an industry leader, Discovery Life Sciences is dedicated not only to improving research methodologies but also to transforming patient outcomes through the development of new therapeutics and diagnostics.

For further information about Discovery's suite of products and services, or to explore the upcoming Tumoroid Cell Lines, visitors can check the company's official website at www.dls.com.

Note: Gibco™ and OncoPro™ are trademarks of Thermo Fisher Scientific and its subsidiaries. The Tumoroid Cell Lines are for Research Use Only and not for diagnostic purposes.